Valproic acid does not affect markers of human immunodeficiency virus disease progression

Beau M. Ances; Scott Letendre; Maria Buzzell; Jennifer Marquie-Beck; Deborah Lazaretto; Thomas D. Marcotte; Igor Grant; Ronald J. Ellis

doi:10.1080/13550280600981695

Valproic acid does not affect markers of human immunodeficiency virus disease progression

Beau M. Ances, Scott Letendre, Maria Buzzell, Jennifer Marquie-Beck, Deborah Lazaretto, Thomas D. Marcotte, Igor Grant, Ronald J. Ellis

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

Original language	English
Pages (from-to)	403-406
Number of pages	4
Journal	Journal of NeuroVirology
Volume	12
Issue number	5
DOIs	https://doi.org/10.1080/13550280600981695
State	Published - Oct 2006

Keywords

CD4+ cell
HIV
Latent virus
Valproic acid
Viral load

Access to Document

10.1080/13550280600981695

Cite this

@article{ba31018be62748da878a64a01b79fd79,

title = "Valproic acid does not affect markers of human immunodeficiency virus disease progression",

abstract = "Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.",

keywords = "CD4+ cell, HIV, Latent virus, Valproic acid, Viral load",

author = "Ances, {Beau M.} and Scott Letendre and Maria Buzzell and Jennifer Marquie-Beck and Deborah Lazaretto and Marcotte, {Thomas D.} and Igor Grant and Ellis, {Ronald J.}",

year = "2006",

month = oct,

doi = "10.1080/13550280600981695",

language = "English",

volume = "12",

pages = "403--406",

journal = "Journal of NeuroVirology",

issn = "1355-0284",

number = "5",

}

TY - JOUR

T1 - Valproic acid does not affect markers of human immunodeficiency virus disease progression

AU - Ances, Beau M.

AU - Letendre, Scott

AU - Buzzell, Maria

AU - Marquie-Beck, Jennifer

AU - Lazaretto, Deborah

AU - Marcotte, Thomas D.

AU - Grant, Igor

AU - Ellis, Ronald J.

PY - 2006/10

Y1 - 2006/10

N2 - Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

AB - Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

KW - CD4+ cell

KW - HIV

KW - Latent virus

KW - Valproic acid

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=33750485028&partnerID=8YFLogxK

U2 - 10.1080/13550280600981695

DO - 10.1080/13550280600981695

M3 - Article

C2 - 17065134

AN - SCOPUS:33750485028

SN - 1355-0284

VL - 12

SP - 403

EP - 406

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

IS - 5

ER -

Valproic acid does not affect markers of human immunodeficiency virus disease progression

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this